Kura Oncology, Inc. (Nasdaq: KURA), a company focused on developing precision medicines for cancer treatment, has achieved a significant milestone in its clinical trials for KO-2806, a next-generation farnesyl transferase inhibitor (FTI).

The company has commenced dosing the first patient with KO-2806 in combination with cabozantinib in the clear cell renal cell carcinoma (ccRCC) cohort of the Phase 1 portion of the FIT-001 trial. This trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of KO-2806 as both a monotherapy and in combination with targeted therapies.

Dr. Stephen Dale, Chief Medical Officer of Kura Oncology, expressed excitement about this milestone, highlighting the potential of combining KO-2806 with tyrosine kinase inhibitors to address resistance mechanisms and enhance antitumor activity.

In addition to the ccRCC cohort, Kura is actively progressing with dose escalation of KO-2806 as a monotherapy and in combination with other targeted therapies. The company plans to begin dosing in combination with adagrasib in KRASG12C-mutant non-small cell lung cancer (NSCLC) in the next quarter.

KO-2806 is designed to improve upon the potency and properties of earlier FTI candidates. Preclinical data presented by Kura Oncology at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics supported the rationale for combining KO-2806 with various targeted therapies.

For more information on the FIT-001 trial, interested parties can refer to the clinical trials database (identifier: NCT06026410).

Kura Oncology's pipeline includes other small molecule drug candidates targeting cancer signaling pathways. Among them, ziftomenib and tipifarnib are undergoing clinical evaluation in different cancer indications.

The company emphasizes that forward-looking statements in this release involve risks and uncertainties, and advises caution in interpreting such statements. Factors such as trial results, regulatory approvals, and financial considerations may affect the actual outcomes.

For further details and updates, visit Kura Oncology's website and follow their announcements on social media platforms.